Search Results - "Dalla Palma, B"

Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation by Giuliani, N, Ferretti, M, Bolzoni, M, Storti, P, Lazzaretti, M, Dalla Palma, B, Bonomini, S, Martella, E, Agnelli, L, Neri, A, Ceccarelli, F, Palumbo, C

“…The involvement of osteocytes in multiple myeloma (MM)-induced osteoclast (OCL) formation and bone lesions is still unknown. Osteocytes regulate bone…”
Get full text

Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: Role of chemokine (C-C motif) ligand 20 by Palma, B Dalla, Guasco, D, Pedrazzoni, M, Bolzoni, M, Accardi, F, Costa, F, Sammarelli, G, Craviotto, L, De Filippo, M, Ruffini, L, Omedè, P, Ria, R, Aversa, F, Giuliani, N

“…The relationship between bone marrow (BM) cytokine and chemokine levels, cytogenetic profiles and skeletal involvement in multiple myeloma (MM) patients is not…”
Get full text

Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human bone marrow osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on the osteogenic differentiation impairment induced by myeloma cells by Bolzoni, M, Donofrio, G, Storti, P, Guasco, D, Toscani, D, Lazzaretti, M, Bonomini, S, Agnelli, L, Capocefalo, A, Dalla Palma, B, Neri, A, Nicolini, F, Lisignoli, G, Russo, F, Colla, S, Aversa, F, Giuliani, N

“…Multiple myeloma (MM) is characterized by the impaired osteogenic differentiation of human mesenchymal stromal cells (hMSCs). Canonical Wnt signaling is…”
Get full text

P58 LOW CD38 EXPRESSION BY PLASMA CELLS IN EXTRAMEDULLARY DISEASE IN MULTIPLE MYELOMA PATIENTS by Notarfranchi, L., Accardi, F., Dalla Palma, B., Mancini, C., Martella, E., Bonomini, S., Storti, P., Toscani, D., Burroughs, J., Marchica, V., Sammarelli, G., Giuliani, N.

Get full text

P39 DEDALO: PHASE II STUDY OF DARATUMUMAB PLUS POMALIDOMIDE AND DEXAMETHASONE (DPD) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND 17P DELETION by Montefusco, V., Cafro, A.M., Margiotta Casaluci, G., Patriarca, F., Mina, R., D'Agostino, M., Capra, A., Priola, C., Dalla Palma, B., Rizzi, R., Genua, A., Petrucci, M.T., Paris, L., Belotti, A., Cavo, M., Conticello, C., Carlo‐Stella, C., Boccadoro, M

Get full text

P850: THE HUMORAL AND CELLULAR RESPONSE TO SARS‐COV‐2 MRNA VACCINATION IN PATIENTS WITH MULTIPLE MYELOMA AND PRE‐MALIGNANT MONOCLONAL GAMMOPATHIES: IMPACT OF OMICRON VARIANT by Storti, P., Marchica, V., Vescovini, R., Franceschi, V., Russo, L., Raimondi, V., Toscani, D., Burroughs Garcia, J., Iannozzi, N. T., Dalla Palma, B., Giaimo, M. T., Notarfranchi, L., Donofrio, G., Giuliani, N.

Get full text

Relationship Between Presence of Osteolytic Lesions, Cytogenetic Features and Bone Marrow Levels of Cytokines and Chemokines in Multiple Myeloma Patients: Role of Chemokine (C-C motif) Ligand 20 as new marker of bone disease by Dalla Palma, B, Guasco, D, Accardi, F, Pedrazzoni, M, Bolzoni, M, Costa, F, Sammarelli, G, Craviotto, L, Bonomini, S, Todaro, G, De Filippo, M, Ruffini, L, Aversa, F, Giuliani, N

Get full text

Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: role of chemokine by Accardi, F, Omede, P, Giuliani, N, Sammarelli, G, Aversa, F, Ruffini, L, Guasco, D, Craviotto, L, Palma, B. Dalla, Ria, R, Pedrazzoni, M, Costa, F, De Filippo, M, Bolzoni, M

“…The relationship between bone marrow (BM) cytokine and chemokine levels, cytogenetic profiles and skeletal involvement in multiple myeloma (MM) patients is not…”
Get full text

S872 CARFILZOMIB LENALIDOMIDE DEXAMETHASONE (KRD) WITH OR WITHOUT TRANSPLANTATION IN NEWLY DIAGNOSED MYELOMA (FORTE TRIAL): EFFICACY ACCORDING TO RISK STATUS by Gay, F., Cerrato, C., Rota Scalabrini, D., Belotti, A., Galli, M., Zamagni, E., Offidani, M., Omedé, P., Monaco, F., Tosi, P., Annibali, O., Pisani, F., Troia, R., Pascarella, A., Ferrara, F., Cea, M., Dalla Palma, B., Patriarca, F., Aquino, S., Palmas, A., Siniscalchi, A., Grasso, M., Palumbo, A., Ledda, A., Musto, P., Cavo, M., Boccadoro, M.

“…Background: High and comparable rates of response and minimal residual disease (MRD) negativity were reported with four 28‐day induction cycles of KRd followed…”
Get full text